3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
1
Solid Tumors
1
Solid Tumor Malignancies
1
Prostatic Neoplasms
1
Lung Neoplasms
1
Carcinoma, Transitional Cell
1
Advanced or Recurrent Solid Tumors
1
Interventions
Paclitaxel
15
atezolizumab
11
Gemcitabine
11
Carboplatin
9
pembrolizumab
8
Docetaxel
8
Irinotecan
7
Bevacizumab
7
Injections
6
Cetuximab
6
Sunitinib
5
Leucovorin
5
Fluorouracil
5
Cyclophosphamide
5
Capecitabine
5
tocilizumab
4
olaparib
4
navitoclax
4
liposomal doxorubicin
4
Topotecan
4
Oxaliplatin
4
Nivolumab
4
Erlotinib Hydrochloride
4
temsirolimus
3
spartalizumab
3
pazopanib
3
lenvatinib
3
fludarabine
3
cobimetinib
3
Cisplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumors
×
vadimezan
×
Clear all
NCT00863733
2009-03-18
DMXAA
Cancer Research UK
Phase 1
Completed
63 enrolled